GLP-1 Use Is Rising: What the 11% Number Means

Important note: This article is for general education only. It is not medical advice. GLP-1 medications require a prescription and medical oversight. Do not start, stop, switch, or change any medication based on survey results, headlines, or social media. If you have questions about GLP-1 medications, side effects, insurance coverage, compounded products, or whether treatment is appropriate for you, talk with your doctor, pharmacist, or another qualified healthcare professional.

GLP-1 medications are no longer a niche topic.

According to a July 2026 Gallup survey, 11% of U.S. adults now report that they are currently taking a GLP-1 medication for weight loss. In 2024, that figure was 3%. Gallup also found that 15% of adults have used one of these medications at some point for weight loss, and 91% say they are aware of the drug class.

That is a major shift in a short period of time.

But the number does not mean one simple thing. It does not mean everyone taking a GLP-1 has the same diagnosis, the same medication, the same coverage, the same side effects, or the same support. It also does not mean that rising use automatically explains every change in national health trends.

What it does show is that GLP-1 medications have moved into the mainstream. That raises important questions about access, safety, affordability, long-term support, and what patients need after the prescription is written.

What Gallup found

Gallup’s 2026 survey found that current GLP-1 use for weight loss has nearly quadrupled since 2024, rising from 3% to 11% of U.S. adults. Lifetime use rose from 6% to 15% over the same period.

Gallup also reported that awareness has become widespread. Ninety-one percent of U.S. adults said they are aware of GLP-1 medications intended for weight loss, up from 80% in 2024.

Those findings matter because awareness can change behavior. A medication that once felt unfamiliar may now come up in doctor’s offices, family conversations, workplace benefits discussions, online communities, and insurance calls.

For patients, that can be helpful. It can make questions easier to ask. But it can also make the space more confusing, especially when brand-name drugs, compounded products, online sellers, oral pills, injections, and social media claims are all part of the same conversation.

What the obesity-rate decline does and does not prove

Gallup also reported that the U.S. adult obesity rate, based on self-reported height and weight, declined from a record 39.9% in 2022 to 36.4% in 2026. Gallup noted that this decline has tracked inversely with increased GLP-1 use.

That is important, but it should be interpreted carefully.

A survey trend can show that two things are moving at the same time. It cannot prove that one caused the other. Gallup also notes that its obesity estimates are based on self-reported height and weight, which can differ from clinical measurements.

So the safer takeaway is this: GLP-1 use is rising, and self-reported obesity rates are declining in Gallup’s data. That pattern is worth watching, but it is not proof that GLP-1 medications alone are responsible for the change.

Public health is complicated. Medication access, food environment, healthcare access, economic stress, physical activity, sleep, stigma, insurance coverage, and social trends can all affect population-level health.

Brand-name, compounded, and “custom-mixed” products are not the same

One of the most important parts of the Gallup report is not just how many people are taking GLP-1s. It is what type of product they say they are using.

Gallup found that 68% of current users reported taking a brand-name prescription medication such as Ozempic, Wegovy, Saxenda, Mounjaro, or Zepbound. Nineteen percent reported using a compounded or custom-mixed version, and 12% were unsure.

Gallup also found that 35% of current compounded or custom-mixed users had switched from a brand-name GLP-1, while 10% of current brand-name users had switched from a compounded or custom-mixed product. Among those who switched from brand-name to compounded, cost or insurance coverage was the most common reason.

That cost pressure is real. But it is also where safety language matters.

Compounded medications are not the same as FDA-approved medications. The FDA states that compounded drugs are not FDA-approved, which means the agency does not review them for safety, effectiveness, or quality before they are marketed. The FDA has also warned about unapproved GLP-1 products, fraudulent compounded products, dosing errors, and misleading marketing.

Glo supports people using doctor-prescribed GLP-1 and GLP-1-related medications. Glo does not support compounded GLP-1 medications or compounded tirzepatide.

If someone has questions about a compounded product, medication source, substitute, supply issue, or online seller, the safest next step is to speak with a licensed prescriber or pharmacist.

Access is expanding, but the rules are still complicated

The rise in GLP-1 use is happening at the same time that access is changing.

On July 1, 2026, the Centers for Medicare & Medicaid Services launched Medicare GLP-1 Bridge, a temporary program that gives eligible Medicare Part D beneficiaries access to certain GLP-1 medications with a $50 monthly copay.

That is a meaningful access change, but it is not universal coverage. CMS says the program operates outside the normal Part D benefit payment flow. The $50 copay does not count toward the Part D deductible or out-of-pocket spending total, and the program is scheduled to run through December 31, 2027.

That kind of detail matters. A headline may say “Medicare covers GLP-1s,” but a patient still has to understand eligibility, prior authorization, plan rules, cost, pharmacy processing, and what happens when a temporary program ends.

Access is not only about whether a drug exists. It is about whether a person can safely, affordably, and consistently use it.

More use means more need for support

When 11% of U.S. adults report currently taking a GLP-1 for weight loss, the question is no longer only whether people will use these medications. Many already are.

The next question is whether they have enough support.

GLP-1 medications can affect appetite, digestion, routines, hydration, food intake, side effects, strength, energy, social eating, travel, and maintenance planning. Some people may need help eating enough protein. Some may need help managing nausea or constipation. Some may need help tracking symptoms. Some may need reminders. Some may need a clearer way to prepare questions for their doctor.

A prescription is not the whole experience.

This is especially important because rapid adoption can create gaps. People may start through different channels, including primary care, specialists, telehealth, private-pay services, employer benefits, Medicare programs, or online platforms. The amount of follow-up and education can vary widely.

A larger GLP-1 population means a larger need for practical, day-to-day support between appointments.

What about health beyond weight?

GLP-1 medications are also being studied and used in a broader metabolic health context.

For example, a July 2026 study summarized by the American Heart Association found that among adults with type 2 diabetes and peripheral artery disease, GLP-1 receptor agonist use was associated with lower all-cause mortality, fewer hospitalizations, fewer amputations, and fewer procedures to restore blood flow compared with metformin users.

That is promising, but it should not be overstated. The American Heart Association noted that more research is needed and that the study could not prove cause and effect.

This is a good example of where GLP-1 science is heading. The drug class is being studied for effects that go beyond weight alone, including cardiovascular, kidney, liver, and metabolic outcomes. But patients should not assume that early or observational findings apply to them personally.

The right question is not “What did a headline say?” It is “What does this mean for my health history, my medication, and my care plan?”

What patients can ask their care team

As GLP-1 use becomes more common, patients may need clearer questions.

If you are taking or considering a doctor-prescribed GLP-1 or GLP-1-related medication, consider asking:

Is this medication approved for my condition?

Is it appropriate for my health history?

What side effects should I watch for?

How should I think about protein, hydration, fiber, and strength?

What should I do if my appetite is very low?

What follow-up do I need?

How will we know if the medication is helping?

What happens if insurance coverage changes?

What should I do if I cannot refill it?

How do I know whether a pharmacy or online provider is legitimate?

Those questions are not signs of hesitation. They are part of informed care.

Where Glo fits in

Glo is designed to support the everyday space between appointments.

For people using doctor-prescribed GLP-1 and GLP-1-related medications, Glo can help track meals, hydration, movement, side effects, symptoms, routines, reminders, and habits by text. It can also help people organize questions for a doctor, pharmacist, registered dietitian, or other care team member.

That kind of support matters more as GLP-1 use becomes more common. More people are starting treatment, but not everyone has a simple way to track what is happening day to day.

Glo does not prescribe medication. It does not replace medical care. It does not verify pharmacies or insurance coverage. It does not support compounded GLP-1 medications or compounded tirzepatide.

But it can help people notice patterns, prepare better questions, and feel less alone between appointments.

Bottom line

Gallup’s 11% number is a sign that GLP-1 medications have entered mainstream American health behavior.

That is important. It may also be only the beginning.

But rising use comes with responsibilities: accurate information, safe prescribing, clearer access rules, better follow-up, and more support for the daily realities of treatment.

The most useful takeaway is not that GLP-1 medications are taking over. It is that millions of people are now using them, and the healthcare system needs to support more than the prescription.

People need guidance. They need safety. They need affordable access. They need help with side effects, routines, food, hydration, movement, and long-term planning.

In GLP-1 care, adoption is only one part of the story. Support is the next one.